RIBAVIRIN - Generic Drug Details

What are the generic sources for ribavirin and what is the scope of patent protection?

Ribavirin is the generic ingredient in five branded drugs marketed by Merck Sharp Dohme, Chartwell Rx, Aurobindo Pharma, Teva, Zydus Pharms Usa, Navinta Llc, Bausch, Schering, Roche, Beximco Pharms Usa, Heritage Pharma Avet, and Sandoz, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for ribavirin. Seven suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for RIBAVIRIN

US Patents:	0
Tradenames:	5
Applicants:	12
NDAs:	16
Drug Master File Entries:	15
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	1,036
Drug Prices:	Drug price trends for RIBAVIRIN
What excipients (inactive ingredients) are in RIBAVIRIN?	RIBAVIRIN excipients list
DailyMed Link:	RIBAVIRIN at DailyMed

See drug prices for RIBAVIRIN

Recent Clinical Trials for RIBAVIRIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Liverpool School of Tropical Medicine	PHASE2
Khyber Medical University Peshawar	PHASE3
University of Oxford	PHASE2

See all RIBAVIRIN clinical trials

Generic filers with tentative approvals for RIBAVIRIN

Applicant	Application No.	Strength	Dosage Form
		40MG/ML	SOLUTION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for RIBAVIRIN

Drug Class

Nucleoside Analog Antiviral

Medical Subject Heading (MeSH) Categories for RIBAVIRIN

Antimetabolites

Antiviral Agents

Anatomical Therapeutic Chemical (ATC) Classes for RIBAVIRIN

J05AP	Antivirals for treatment of HCV infections
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for RIBAVIRIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIRAZOLE	for Inhalation Solution	ribavirin	6 gm/vial	018859	1	2014-05-22

US Patents and Regulatory Information for RIBAVIRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heritage Pharma Avet	RIBAVIRIN	ribavirin	TABLET;ORAL	077053-001	Dec 5, 2005		DISCN	No	No
Beximco Pharms Usa	RIBAVIRIN	ribavirin	TABLET;ORAL	202546-004	Aug 12, 2014		DISCN	No	No
Navinta Llc	RIBAVIRIN	ribavirin	FOR SOLUTION;INHALATION	207366-001	Oct 6, 2016		RX	No	Yes

Expired US Patents for RIBAVIRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003

EU/EMA Drug Approvals for RIBAVIRIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Rebetol	ribavirin	EMEA/H/C/000246Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.	Withdrawn	no	no	no	1999-05-06
Teva B.V.	Ribavirin Teva Pharma B.V.	ribavirin	EMEA/H/C/001064Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).	Withdrawn	yes	no	no	2009-07-01
Teva B.V.	Ribavirin Teva	ribavirin	EMEA/H/C/001018Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2009-03-31

Market Dynamics and Financial Trajectory for Ribavirin

Last updated: February 20, 2026

Ribavirin is an antiviral medication primarily used to treat hepatitis C virus (HCV) infection and other viral diseases. The drug has been in use for decades, with a well-established position in antiviral therapy. Its market landscape, financial performance, and future prospects are influenced by evolving healthcare policies, technological innovations, patent statuses, and emerging therapies.

Market Overview

Historical Context:
Developed in the 1970s, ribavirin received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) in 1986. Its initial use involved broad-spectrum antiviral activity, but in recent years, its role has diminished due to more effective therapies.

Current Indications:

• Combination with pegylated interferon for hepatitis C.
• Treatment for respiratory syncytial virus (RSV) in infants and immunocompromised patients.
• Off-label uses include treatment for some viral hemorrhagic fevers and viral encephalitis.

Market Size and Trends:

• The global antiviral market was valued at approximately USD 48.2 billion in 2022, with the hepatitis C segment representing significant revenue share in the mid-2010s.
• Ribavirin's market share has declined markedly, given the advent of direct-acting antiviral agents (DAAs).
• The estimated global sales of ribavirin were approximately USD 200 million in 2022, primarily driven by legacy treatments and specialized applications.

Competitive Landscape

Major Players:

• Merck & Co. (product: Copegus)
• Boehringer Ingelheim (product: Rebetol)
• Cipla, Dr. Reddy's Laboratories, and other generic manufacturers.

Patent and Regulatory Status:

• Many formulations of ribavirin are off patent, increasing availability of generics, which exert downward pressure on prices.
• The original patents expired in the late 2000s, leading to increased competition and reduced revenues for brand-name manufacturers.

Pricing and Reimbursement Dynamics

Pricing Trends:

• Ranged from USD 900 to USD 1,500 per 600 mg capsules, depending on region and formulation.
• Generics have reduced prices by approximately 50-70% over the last decade.

Reimbursement Policies:

• In highly regulated markets (U.S., Europe), reimbursement depends on inclusion in national drug formularies and treatment guidelines.
• Reimbursement levels are generally lower for off-patent products.

Future Market Trajectory

R&D and Pipeline Development:

• Minimal ongoing R&D specific to ribavirin; most innovation centers on specific formulations or combination regimens.
• New therapies, especially DAAs, have rendered ribavirin largely obsolete for hepatitis C.

Market Outlook:	Year	Estimated Global Sales (USD millions)	Key Factors Influence
2023	200	Declining use in hepatitis C; specialized applications persist
2025	170	Continued substitution by DAAs; generics dominate sale
2030	100 or less	Further displacement by newer antiviral therapies

Drivers of Decline:

• Availability of highly effective, interferon-free DAA regimens with cure rates exceeding 95%.
• Changing treatment guidelines favoring newer agents.
• Patient preference for oral, shorter-duration therapies.

Potential Niche Uses:

• Reauthentication for RSV, particularly in pediatric and immunocompromised settings.
• Development of fixed-dose combinations with other antivirals for niche indications.

Financial Considerations

Revenue Patterns:

• Revenues peaked in the early 2010s, around USD 600-700 million annually, driven by hepatitis C treatments.
• Current revenues have declined by approximately 70%, reflecting reduced demand.

Profitability:

• Legacy formulations remain profitable for generic manufacturers due to low production costs.
• Brand-name manufacturers face shrinking margins as patent expiries expand generics.

Investment Outlook:

• Little new investment in R&D specifically targeting ribavirin.
• Market remains stable in niche applications but shows limited growth prospects overall.

Regulatory Environment

FDA & EMA Policies:

• No recent unprecedented regulatory changes impacting ribavirin.
• Focus on approval and regulation of new antiviral combinations.

Global Access Initiatives:

• Initiatives aim to improve access to affordable generics, especially in low- and middle-income countries, sustaining market presence.

---

Key Takeaways

• Ribavirin's global market size declined substantially from historic levels, driven by the advent of highly effective DAAs for hepatitis C.
• Patent expirations and availability of generics have placed significant price and revenue pressure on brand manufacturers.
• The drug remains in use for niche indications, such as RSV in certain populations, despite limited growth prospects.
• Sales are projected to fall below USD 100 million by 2030, with minimal R&D activity focused on this drug.
• The regulatory environment favors newer therapies, further diminishing ribavirin's market share.

---

FAQs

Q1: Will ribavirin regain market share against newer antivirals?
A: Unlikely; the superior efficacy and tolerability of DAAs have replaced ribavirin in most hepatitis C treatment protocols.

Q2: What are the primary factors supporting current ribavirin sales?
A: Off-label use, niche indications like RSV, and low-cost generics in developing markets.

Q3: Are there ongoing formulations or delivery innovations for ribavirin?
A: Limited; most recent developments focus on combination therapies rather than standalone formulations.

Q4: How does ribavirin compare in cost to its competitors?
A: Significantly cheaper as a generic; original brand products are more expensive but have limited market relevance.

Q5: What are future regulatory changes expected to influence ribavirin?
A: No major regulatory shifts are anticipated; the focus remains on approving and integrating newer antiviral agents.

---

References

1. World Health Organization. (2022). Global hepatitis report. WHO.
2. MarketWatch. (2023). Antiviral drugs market size and forecast.
3. U.S. Food and Drug Administration. (2022). Approved antiviral drugs.
4. IQVIA. (2022). Global pharmaceutical sales data.
5. Grand View Research. (2022). Hepatitis C therapeutics market analysis.